Anzeige
Mehr »
Donnerstag, 22.01.2026 - Börsentäglich über 12.000 News
Gold-Alarm aus Kanada: Über 200 Meter Gold
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 899376 | ISIN: US5147661046 | Ticker-Symbol: LDE
Tradegate
20.01.26 | 15:42
7,000 Euro
-2,78 % -0,200
1-Jahres-Chart
LIFECORE BIOMEDICAL INC Chart 1 Jahr
5-Tage-Chart
LIFECORE BIOMEDICAL INC 5-Tage-Chart
RealtimeGeldBriefZeit
7,1007,40010:28
7,1007,40010:22

Aktuelle News zur LIFECORE BIOMEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrLifecore Biomedical, Inc.: Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)1
FrLIFECORE BIOMEDICAL, INC. \DE\ - 8-K, Current Report1
13.01.Grabar Law Office: Notice to Long-Term Shareholders of Lifecore Biomedical, Inc. (LFCR): Grabar Law Office Investigates Claims on Your Behalf as Securities Fraud Class Action Settles283Philadelphia, Pennsylvania--(Newsfile Corp. - January 13, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of Lifecore Biomedical, Inc. (NASDAQ: LFCR) as a securities...
► Artikel lesen
08.01.Grabar Law Office: Notice to Long-Term Shareholders of Lifecore Biomedical, Inc. (LFCR): Grabar Law Office Investigates Claims on Your Behalf as Securities Fraud Class Action Reaches Settlement720Philadelphia, Pennsylvania--(Newsfile Corp. - January 8, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of Lifecore Biomedical, Inc. (NASDAQ: LFCR) The investigation...
► Artikel lesen
30.12.25Grabar Law Office: Notice to Long-Term Shareholders of Lifecore Biomedical, Inc. (LFCR): Grabar Law Office Investigates Claims on Your Behalf as Securities Fraud Class Action Reaches Settlement956Philadelphia, Pennsylvania--(Newsfile Corp. - December 30, 2025) - Grabar Law Office is investigating claims on behalf of shareholders of Lifecore Biomedical, Inc. (NASDAQ: LFCR) The investigation...
► Artikel lesen
29.12.25KeyBanc maintains Sector Weight rating on Lifecore Biomedical stock2
LIFECORE BIOMEDICAL Aktie jetzt für 0€ handeln
18.12.25Lifecore Biomedical, Inc.: Lifecore Biomedical to be Added to Nasdaq Biotech Index141CHASKA, Minn., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced...
► Artikel lesen
17.12.25Lifecore gewinnt globalen Pharmakonzern als neuen CDMO-Kunden2
17.12.25Lifecore Biomedical, Inc.: Lifecore Biomedical Signs CDMO Master Services Agreement with New Large Multinational Pharmaceutical Customer141Agreement Calls for Development Services and Tech Transfer in Preparation for Commercial Manufacturing of Injectable Pharmaceutical Product Partner's Program Size Positions it to Become a Top Five...
► Artikel lesen
17.11.25LIFECORE BIOMEDICAL, INC. \DE\ - 8-K, Current Report-
10.11.25Here's the Analysis of LifeCore's (LFCR) Growth Potential2
07.11.25Lifecore outlines $74M-$76M revenue target for transition period while advancing commercial wins and margin expansion7
06.11.25Lifecore Biomedical übertrifft Prognosen für Q3 2025, Aktie gibt dennoch nach1
06.11.25LIFECORE BIOMEDICAL, INC. \DE\ - 10-Q, Quarterly Report-
01.11.25Lifecore Biomedical: EPS übertrifft Schätzungen - Umsatz schlechter als erwartet1
31.10.25LIFECORE BIOMEDICAL, INC. \DE\ - 8-K, Current Report1
30.10.25Lifecore Biomedical, Inc.: Lifecore Biomedical to Report Financial Results for the Three Months Ended September 30, 2025, on November 6, 20251
29.10.25Lifecore Selected as Commercial Mfg. Partner for Leading Injectable Product1
29.10.25Lifecore Biomedical, Inc.: Lifecore Biomedical Selected as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company200Lifecore to Execute Commercial Site Transfer and Become New Supplier of Choice for Leading Commercial Injectable Pharmaceutical Product Represents Second Agreement Signed with Same Major Multinational...
► Artikel lesen
29.10.25Lifecore and PolyPeptide link for US peptide manufacturing4
Weiter >>
40 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1